AI Summary
Multiple sclerosis is a neurodegenerative disorder with variable outcomes. Over 200 genetic variants have been linked to the development of multiple sclerosis, mainly in genes expressed by immune cells. Current therapies target lymphocytes but some patients still experience neurological disability.
Multiple sclerosis is an autoimmune, neurodegenerative disorder with highly variable long-term outcomes.1 More than 200 common autosomal variants have been associated with the risk of developing multiple sclerosis.2 These established risk variants map almost exclusively to genes expressed by peripheral immune cells and CNS-resident microglia. Immunomodulatory disease-modifying therapies target lymphocytes, and particularly B cells, to prevent clinical and radiological inflammatory activity.3 However, despite the availability of these therapies, insidious neurological disability continues to accumulate in some patients.